4.6 Article

Multiple sclerosis

期刊

NATURE REVIEWS DISEASE PRIMERS
卷 4, 期 -, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41572-018-0041-4

关键词

-

资金

  1. ARiSLA (Fondazione Italiana di Ricerca per la SLA)
  2. Fondazione Italiana Sclerosi Multipla
  3. Italian Ministry of Health
  4. Biogen Idec
  5. Celgene/Receptos
  6. Merck/EMD Serono
  7. Roche/Genentech
  8. Biogen
  9. Genzyme
  10. Novartis
  11. Celgene
  12. Roche
  13. Sanofi-Aventis
  14. Teva
  15. GlaxoSmithKline
  16. Medimmune
  17. Sanofi-Genzyme
  18. Merck-Serono
  19. MedDay

向作者/读者索取更多资源

Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. This disorder is a heterogeneous, multifactorial, immune-mediated disease that is influenced by both genetic and environmental factors. In most patients, reversible episodes of neurological dysfunction lasting several days or weeks characterize the initial stages of the disease (that is, clinically isolated syndrome and relapsing-remitting MS). Over time, irreversible clinical and cognitive deficits develop. A minority of patients have a progressive disease course from the onset. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, which can be associated with neuro-axonal damage. Focal lesions are thought to be caused by the infiltration of immune cells, including T cells, B cells and myeloid cells, into the central nervous system parenchyma, with associated injury. MS is associated with a substantial burden on society owing to the high cost of the available treatments and poorer employment prospects and job retention for patients and their caregivers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据